Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/88098
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.contributorChinese Mainland Affairs Office-
dc.creatorLee, MML-
dc.creatorChan, BD-
dc.creatorWong, WY-
dc.creatorLeung, TW-
dc.creatorQu, Z-
dc.creatorHuang, JR-
dc.creatorZhu, LZ-
dc.creatorLee, CS-
dc.creatorChen, SB-
dc.creatorTai, WCS-
dc.date.accessioned2020-09-18T02:12:42Z-
dc.date.available2020-09-18T02:12:42Z-
dc.identifier.issn2470-1343-
dc.identifier.urihttp://hdl.handle.net/10397/88098-
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.rights© 2020 American Chemical Societyen_US
dc.rightsThis is an open access article published under an ACS AuthorChoice License (https://pubs.acs.org/page/policy/authorchoice_termsofuse.html), which permits copying and redistribution of the article or any adaptations for non-commercial purposes.en_US
dc.rightsThe following publication Lee, M. M. L., Chan, B. D., Wong, W. Y., Leung, T. W., Qu, Z., Huang, J. R., . . . Tai, W. C. S. (2020). Synthesis and evaluation of novel anticancer compounds derived from the natural product brevilin A. Acs Omega, 5(24), 14586-14596 is available at https://dx.doi.org/10.1021/acsomega.0c01276en_US
dc.titleSynthesis and evaluation of novel anticancer compounds derived from the natural product brevilin Aen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage14586-
dc.identifier.epage14596-
dc.identifier.volume5-
dc.identifier.issue24-
dc.identifier.doi10.1021/acsomega.0c01276-
dcterms.abstractCancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018, and this burden continues to increase. Therefore, there is a clear and urgent need for novel drugs with increased efficacy for the treatment of different cancers. Previous research has demonstrated that brevilin A (BA) exerts anticancer activity in various cancers, including human multiple myeloma, breast cancer, lung cancer, and colon carcinoma, suggesting the anticancer potential present in the chemical scaffold of BA. Here, we designed and synthesized a small library of 12 novel BA derivatives and evaluated the biological anticancer effects of the compounds in various cancer cell lines. The results of this structure-activity relationship study demonstrated that BA derivatives BA-9 and BA-10 possessed significantly improved anticancer activity toward lung, colon, and breast cancer cell lines. BA-9 and BA-10 could more effectively reduce cancer cell viability and induce DNA damage, cell-cycle arrest, and apoptosis when compared with BA. Our findings represent a significant step forward in the development of novel anticancer entities.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationACS omega, 2020, v. 5, no. 24, p. 14586-14596-
dcterms.isPartOfACS omega-
dcterms.issued2020-
dc.identifier.isiWOS:000543740600041-
dc.identifier.scopus2-s2.0-85087403319-
dc.identifier.pmid32596596-
dc.description.validate202009 bcrc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Lee_Anticancer_Brevilin_A.pdf4.1 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

69
Citations as of Jun 26, 2022

Downloads

68
Citations as of Jun 26, 2022

SCOPUSTM   
Citations

6
Citations as of Jun 23, 2022

WEB OF SCIENCETM
Citations

7
Citations as of Jun 23, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.